Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win

Focused on therapies for rare skin diseases, this clinical-stage biotech saw a notable director purchase coincide with a decisive Phase 3 trial announcement and the closing of a $230 million equity offering.